Peculiar laryngeal mask airway packaging results in failed ventilation when used as a rescue airway device during an anaesthetic crisis
We would like to alert clinicians to the packaging design of the Ambu® AuraGain™ (Ambu A/S, Ballerup, Denmark) laryngeal mask airway (LMA), in which the pilot balloon lies deeply embedded within the ventilating channel. We report a case of failed ventilation of a patient when the device was inserted straight from its packet as a rescue airway during an anaesthetic crisis.
Our patient, an obese 68-year-old man with necrotising fasciitis of his perineum who was undergoing a dressing change in the lithotomy position, has provided his consent for publication. He had been intubated following a rapid sequence induction (Cormack and Lehane Grade 2), but part way into the procedure had become un-ventilatable after a tenacious mucous plug had occluded his endotracheal tube proximal to the Murphy's eye. With potential for difficult bag-mask ventilation, and having already dropped his oxygen saturation to 70%, a size four AuraGain disposable LMA was chosen as a rescue device to expedite oxygenation whilst plans were made for re-intubation.
The Ambu AuraGain is the standard second-generation LMA used at our institution. Given the urgency of the situation, the LMA was removed from its packaging and inserted directly into the patient without first checking or preparing the device. The anaesthetic assistant subsequently sought to inflate the pilot balloon but the balloon could not be found. Significant nursing resources were expended in searching for the pilot balloon, which proved a major distraction. Despite inadequate ventilation through the device, the patient could fortunately still be oxygenated. After oxygen saturation had improved to 95%, the patient was re-intubated and the surgery permitted to continue as planned.
Upon removal of the LMA the pilot balloon was found occluding the ventilation aperture of the device-the configuration in which the device is found in its packaging ( Figure 1 ). It is suspected that the positioning of the balloon effectively created a one-way valve, in which oxygen was able to pass into the patient's lungs, but very little carbon dioxide could return back through the ventilation channel. Minimal carbon dioxide was seen on the capnography trace. Carbon dioxide was, however, able to exit the lungs through the large leak around the cuff. Of note, high-pressure hand ventilation through the device (with the adjustable pressure limiting valve completely closed) failed to dislodge the pilot balloon from the aperture.
The peculiar packaging of this device is not a once-off anomaly isolated to the LMA used in our patient, but is instead the current standard packaging design for all Ambu Correspondence AuraGain laryngeal mask airways. This had escaped the notice of many clinicians in our hospital prior to this potentially lifethreatening incident. The packaging design is unique to Ambu devices that incorporate an anatomically curved airway tube component (AuraGain™, Aura-I™, AuroOnce™ and Aura40™). It is not shared by other LMA brands used in our facility and is not a feature of the AuraStraight™ or AuraFlex™ laryngeal mask airways supplied by the same company.
Anaesthetic crisis guidelines and protocols recommend the use of a supraglottic airway such as an LMA as an initial rescue device in situations in which bag-mask ventilation or endotracheal intubation is difficult or fails [1] [2] [3] [4] . There are advantages to using a second-generation LMA over a firstgeneration device in airway emergencies including the higher ventilation pressures that can be achieved and the ability to pass an orogastric tube to deflate stomach gas and suction gastric contents. Many such devices, including the Ambu AuraGain, may also act as a conduit through which an endotracheal tube may be placed. Since these devices are specifically indicated for airway crises, it is foreseeable that they may at times be used without first being optimally prepared. This is particularly so in an era where cuffless laryngeal mask airways (I-gel™ range) (Intersurgical Ltd, Berkshire, UK) are in widespread use.
Clinicians should be aware of this potential pitfall when using the Ambu AuraGain device and are strongly urged to ensure that the pilot balloon is first manually removed from the ventilating channel prior to patient use. Our incident reinforces the benefit of checking all equipment, even-and perhaps especially in-emergency situations. As human factors can never be removed from anaesthetic emergencies, equipment and its packaging should always be engineered in such a way to minimise or eliminate any potential risk. Our safety concerns regarding the packaging of the AuraGain device have been reported to the manufacturer, both verbally and in writing, and an alert has been submitted to the Therapeutic Goods Administration.
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